Abstract
Malaria caused by Plasmodium falciparum continues to be a major public health problem especially in tropical and sub-tropical regions of the world. Considering the growing resistance of parasites to anti-malarial drugs and of vector mosquitoes to insecticides, there is no doubt that the effective vaccine is the most awaiting tool to reduce the risk of malaria. Our synthetic studies have shown that a loop region (AD22 = 256ASEFYNSENKTYDLDFKTPNND277) of Plsmodium falciparum enolase has antigenic reactivity against patients’ sera and AD22 can produce inhibitory antibodies against in vitro parasite growth. In this paper, we will briefly present our ongoing research of malaria vaccine development and related model studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
